Anthony J. Gringeri

Centocor, Inc. manufactures healthcare products. Its products include avakine & reopro. The company was founded in 1979 by Hubert J. P. Schoemaker & Michael A. Wall and is headquartered in Horsham, PA.

The Bill & Melinda Gates Foundation was formed in 1997 as the William H. Gates Foundation. In 1999, the foundation was renamed the Bill & Melinda Gates Foundation. The Bill & Melinda Gates Foundation Trust was created in January 2000 through the merger of the Gates Learning Foundation, which worked to expand access to technology through public libraries and the William H. Gates Foundation, which focused on improving global health. The foundation participates in preventive approaches and collaborative endeavors with government, philanthropic and not-for-profit partners. Priority is given to grants that leverage additional support and serve as a catalyst for long-term, systemic change. The foundation also provides funds to promote greater equity in global health, education and public libraries. Through their partnerships in communities across the US, the Bill & Melinda Gates Foundation is committed to raising the high school graduation rate and helping all students, regardless of race or family income. The foundation is headquartered in Seattle, Washington.

Alantos Pharmaceuticals Holding, Inc. manufactures bio-pharmaceutical products. The firm develops small molecule compounds for inflammatory cytokine pathways. The company was founded in 1999 and is headquartered in Thousand Oaks, CA.

BioVex, Inc. develops vaccines for the treatment of cancer and the prevention of chronic infectious diseases. Its products include OncoVEX oncolytic and ImmunoVEX technology. The company was founded in 1999 by Dr. Robert Coffin and is headquartered in Woburn, MA.

BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA.

Part of Forbion Capital Partners Management Holding BV, the venture capital firm, Forbion Co-Investment II Coöperatief UA, is based in Naarden, Netherlands. Forbion Co-Investment II Coöperatief UA operates as a venture capital firm. The Dutch company was founded in 2000 by Bart Bergstein, Hugo Alexander Slootweg, Martien van Osch.

University of Southern California is a private research university that mainly offers undergraduate, graduate & other higher education. The university was founded in 1880 and is headquartered in Los Angeles, CA.

Xention Pharma Ltd. develops and researches drugs. The firm develops novel therapies for the treatment of atrial fibrillation; modulators of IKur and IKACh for atrial fibrillation. The company was founded by John W. Word and is headquartered in Newmarket, the United kingdom.

The American Institute of Certified Public Accountants provides vocational education in accounting. The company provides services to the accounting community, regulatory bodies, and other organizations. It also operates in Jersey City, Washington, and Lewisville. It was founded in 1887 and is headquartered in New York City, NY.

Pulmagen Therapeutics (Synergy) Ltd. develops therapeutics for respiratory diseases. It engages in developing various internal proprietary programs in chronic obstructive pulmonary disease, asthma, and cystic fibrosis. The company was founded in August 2000 and is headquartered in Stevenage, the United Kingdom.

Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland.

Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies.

Pepscan Therapeutics BV develops immunotherapeutic products in oncology. The company was founded in 2000 and is headquartered in Lelystad, the Netherlands.

Oxyrane UK Ltd. engages in the development of novel enzyme replacement therapies for lysosomal storage disorders. Its product is a pre-clinical ERT for Pompe Disease - a serious muscle disease - produced using engineered yeast cells. The firm develops recombinant enzyme products using a proprietary, engineered yeast expression platform based on Yarrowia lipolytica. The company was founded by Robin Kumar Mitra, Adriana L. Botes and Michael Campbell in 2006 and is headquartered in Manchester, the United Kingdom.

Janssen Biologics BV manufactures, acquires and markets biopharmaceutical therapies. The firms products focus on cardiovascular and immunological disorders, and cancer. The company was founded in 1984 and is headquartered in Leiden, the Netherlands.

nLife Therapeutics SL develops and manufactures pharmaceutical preparations. It specializes in oligonucleotides as therapeutic agents for central nervous system and neuromuscular disorders. The company was founded by Andres Pablo Montefeltro on September 24, 2009 and is headquartered in Armilla, Spain.

Part of Xention Pharma Ltd., Xention Ltd. is a British company that develops and researches drugs. The company is based in Newmarket, UK. Xention was founded in 2002.

NeuExCell Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in State College, PA.

Nacuity Pharmaceuticals, Inc. develops and markets pharmaceutical products. The company is headquartered in Fort Worth, TX.

NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands.

Azafaros BV develops therapeutic agents for the treatment of rare metabolic disorders. The company was founded on July 1, 2018 and is headquartered in Leiden, the Netherlands.

Impella Cardiosystems AG develops, manufactures, and markets minimally invasive cardiovascular support systems. The company is based in Aachen, Germany. The German company was founded by Thorsten Sieß.

Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million.

VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation.